AR060525A1 - Piridin [3,4-b] pirazinonas. composiciones farmaceuticas - Google Patents
Piridin [3,4-b] pirazinonas. composiciones farmaceuticasInfo
- Publication number
- AR060525A1 AR060525A1 ARP070101657A ARP070101657A AR060525A1 AR 060525 A1 AR060525 A1 AR 060525A1 AR P070101657 A ARP070101657 A AR P070101657A AR P070101657 A ARP070101657 A AR P070101657A AR 060525 A1 AR060525 A1 AR 060525A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- independently selected
- alkyl
- alkynyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Se dan a conocer también las correspondientes composiciones farmacéuticas. Reivindicacion 1: Un compuesto, o una sal farmacéuticamente aceptable del compuesto, en el que el compuesto tiene la estructura de formula 1, y en la que: R2 se selecciona del grupo constituido por arilo y anillo heterociclilo de 3 a 10 miembros, en la que dichos sustituyentes arilo y heterociclilo R2 pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, nitro, oxo, alquilo, alquenilo, alquinilo, cicloalquilo, -OR201, -C(O)R201, -OC(O)R201, -C(O)OR201, -NR201R202, -N(R202)C(O)R202, -C(O)NR201R202, -C(O)NR201C(O)R202, -SR201, -S(O)R201, y -S(O)2R201, en los que dichos sustituyentes alquilo, alquenilo, alquinilo y cicloalquilo pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, oxo, -OR203 y -C(O)OR203; R201, R202 y R203 se seleccionan independientemente del grupo constituido por hidrogeno y alquilo, en el que dicho alquilo puede estar opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, hidroxi, alcoxi, carboxi y - C(O)NH2; R6A y R6B, junto con el nitrogeno al que están unidos, forman un anillo heterociclilo parcial o totalmente saturado de 3 a 14 miembros, en el que el heterociclilo puede estar opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo constituido por hidrogeno, halogeno, oxo, alquilo, alquenilo, alquinilo, ciano, cicloalquilo, arilo y heterociclilo, -OR601, -C(O)R601, -OC(O)R601, -C(O)OR601, -NR6011R602, -N(R601)C(O)R602, - C(O)NR601R602, -C(O)NR601C(O)R602, en los que (a) dichos sustituyentes alquilo, alquenilo, alquinilo y cicloalquilo pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, oxo, -OR603, -C(O)R603, -C(O)OR603, -OC(O)R603, -NR603R604, -N(R603)C(O)R604, -C(O)NR603R604, -C(O)NR603C(O)R604, -SR603, -S(O)R603, -S(O)2R603, -N(R603)S(O)2R604, y -S(O)2NR603R604, C(O)NR603C(O)R604, -SR603, -S(O)R603, -S(O)2R603, -N(R603)S(O)2R604, y -S(O)2NR603R604, y (b) dichos sustituyentes arilo y heterociclilo pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, alquilo, alquenilo, alquinilo, ciano, oxo, -OR601, -C(O)R601, -C(O)OR601, -OC(O)R601, -NR601R602, -N(R601)C(O)R602, -C(O)NR601R602, -C(O)NR601C(O)R602, -SR601, -S(O)R602, -S(O)2R601, -N(R601)S(O)2R602, y -S(O)2NR601R602; R601, R602, R603 y R604 se seleccionan independientemente del grupo constituido por hidrogeno, alquilo, alquenilo y alquinilo, en el que (a) dicho alquilo R601 y R602 puede estar opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, hidroxi, carboxi, oxo, alquenilo, alquinilo, haloalquenilo, hidroxialquenilo, carboxialquilo, haloalquinilo, hidroxialquinilo, carboxialquinilo, alcoxi, haloalcoxi, hidroxialcoxi y carboxialcoxi, y (b) dichos sustituyentes alquenilo y alquinilo R601 y R602 pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, hidroxi, carboxi, oxo, alcoxi, haloalcoxi, hidroxialcoxi y carboxialcoxi; R8 es alquilo; en el que dicho sustituyente R8 puede estar opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, hidroxi, carboxi, alquenilo, alquinilo, - OR801, -C(O)R801, -C(O)OR801, -OC(O)R801, -NR801R802, -N(R801)C(O)R802, -C(O)NR801R802, y -C(O)NR801C(O)R802, en el que dichos sustituyentes alquenilo y alquinilo pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, hidroxi, carboxi, oxo y alcoxi; y R801 y R802 se seleccionan independientemente del grupo constituido por hidrogeno, alquilo, alquenilo y alquinilo, en el que (a) cuando dicho alquilo es metilo, dicho metilo puede estar opcionalmente sustituido con 1, 2 o 3 sustituyentes fluoro, (b) cuando dicho alquilo comprende al menos dos átomos de carbono, dicho alquilo puede estar opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, hidroxi, carboxi, oxo, alquinilo, haloalquinilo, hidroxialquinilo, carboxialquinilo, alcoxi, haloalcoxi, hidroxialcoxi y carboxialcoxi, y (c) dichos sustituyentes alquenilo y alquinilo R801 y R802 pueden estar opcionalmente sustituidos con uno o más sustituyentes independientemente seleccionados del grupo constituido por halogeno, ciano, hidroxi, carboxi, oxo, alcoxi, haloalcoxi, hidroxialcoxi y carboxialcoxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79397106P | 2006-04-21 | 2006-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR060525A1 true AR060525A1 (es) | 2008-06-25 |
Family
ID=38431249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070101657A AR060525A1 (es) | 2006-04-21 | 2007-04-18 | Piridin [3,4-b] pirazinonas. composiciones farmaceuticas |
Country Status (42)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0710658A2 (pt) | 2006-04-21 | 2011-08-16 | Pfizer Prod Inc | compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
| AU2007333115B2 (en) * | 2006-12-12 | 2013-01-10 | Gilead Sciences, Inc. | Composition for treating a pulmonary hypertension |
| EA020372B1 (ru) * | 2008-03-05 | 2014-10-30 | Мерк Патент Гмбх | Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета |
| WO2010041711A1 (ja) * | 2008-10-09 | 2010-04-15 | 杏林製薬株式会社 | イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤 |
| KR101903925B1 (ko) * | 2009-10-26 | 2018-10-02 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| KR20130069855A (ko) | 2010-10-15 | 2013-06-26 | 길리애드 사이언시즈, 인코포레이티드 | 폐 고혈압 치료의 조성물 및 방법 |
| EP2691393B1 (en) | 2011-03-31 | 2016-09-14 | Pfizer Inc | Novel bicyclic pyridinones |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| WO2013030713A1 (en) | 2011-08-31 | 2013-03-07 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds |
| EP2852597B1 (en) | 2012-05-04 | 2016-06-08 | Pfizer Inc | Heterocyclic substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of app, bace1 and bace 2. |
| EP2897964A1 (en) | 2012-09-20 | 2015-07-29 | Pfizer Inc. | Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| CA2893256A1 (en) | 2012-12-11 | 2014-06-19 | Pfizer Inc. | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1 |
| EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
| EP2956458B1 (en) | 2013-02-13 | 2017-08-09 | Pfizer Inc | Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| US9233981B1 (en) | 2013-02-15 | 2016-01-12 | Pfizer Inc. | Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds |
| EP2958915B1 (en) | 2013-02-19 | 2017-07-05 | Pfizer Inc | Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders |
| CA2925743C (en) | 2013-10-04 | 2018-03-06 | Pfizer Inc. | Novel bicyclic pyridinones as gamma-secretase modulators |
| JO3466B1 (ar) * | 2013-12-20 | 2020-07-05 | Takeda Pharmaceuticals Co | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 |
| KR101886945B1 (ko) | 2014-04-01 | 2018-08-08 | 화이자 인코포레이티드 | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 |
| EA030085B1 (ru) | 2014-04-10 | 2018-06-29 | Пфайзер Инк. | 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| JP6506833B2 (ja) | 2014-08-06 | 2019-04-24 | ファイザー・インク | イミダゾピリダジン化合物 |
| JP6628805B2 (ja) | 2015-02-03 | 2020-01-15 | ファイザー・インク | 新規シクロプロパベンゾフラニルピリドピラジンジオン |
| SG10201912333PA (en) | 2015-06-17 | 2020-02-27 | Pfizer | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| JP2018531924A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用 |
| JP2018531923A (ja) | 2015-09-24 | 2018-11-01 | ファイザー・インク | Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド |
| JP2018534251A (ja) | 2015-09-24 | 2018-11-22 | ファイザー・インク | Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド |
| CA3015166C (en) | 2016-02-23 | 2021-08-03 | Pfizer Inc. | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds |
| EP3478679B1 (en) | 2016-07-01 | 2021-04-21 | Pfizer Inc. | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
| DK3642202T3 (da) | 2017-06-22 | 2023-01-30 | Pfizer | Dihydro-pyrrolo-pyridin-derivater |
| US11382918B2 (en) * | 2017-06-28 | 2022-07-12 | Ptc Therapeutics, Inc. | Methods for treating Huntington's Disease |
| PT3768669T (pt) | 2018-03-23 | 2023-04-24 | Pfizer | Derivados de piperazina azaspiro |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1361652A (fr) | 1963-06-21 | 1964-05-22 | Ciba Geigy | Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine |
| DE69132340T2 (de) * | 1990-11-06 | 2001-02-08 | Yamanouchi Pharma Co Ltd | Kondensiertes pyrazinderivat |
| TW274550B (es) * | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
| JP2000154139A (ja) | 1998-09-16 | 2000-06-06 | Kyowa Hakko Kogyo Co Ltd | 縮環ピラジン誘導体 |
| US6369056B1 (en) * | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6465465B1 (en) | 2000-03-14 | 2002-10-15 | Arzneimittelwerk Dresden Gmbh | Process for the treatment of erectile dysfunction and product therefor |
| EP1364950A4 (en) * | 2001-02-26 | 2005-03-09 | Tanabe Seiyaku Co | PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE |
| WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| US20030114469A1 (en) * | 2001-09-27 | 2003-06-19 | Cohen David Saul | Combinations |
| US7067658B2 (en) * | 2002-09-30 | 2006-06-27 | Bristol-Myers Squibb Company | Pyridino and pyrimidino pyrazinones |
| WO2005040337A2 (en) * | 2003-05-20 | 2005-05-06 | The Regents Of The University Of California | METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES |
| EP1641423B1 (en) * | 2003-06-26 | 2010-03-17 | Merck Sharp & Dohme Corp. | Benzodiazepine cgrp receptor antagonists |
| DE102004033670A1 (de) * | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
| CA2593005A1 (en) * | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof |
| CA2608672A1 (en) * | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| CN101296910A (zh) * | 2005-08-26 | 2008-10-29 | 梅特希尔基因公司 | 组蛋白脱乙酰酶的苯并二氮杂卓和苯并哌嗪类似物抑制剂 |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| BRPI0710658A2 (pt) | 2006-04-21 | 2011-08-16 | Pfizer Prod Inc | compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos |
-
2007
- 2007-04-10 BR BRPI0710658-0A patent/BRPI0710658A2/pt not_active IP Right Cessation
- 2007-04-10 EP EP07734320A patent/EP2013208B1/en active Active
- 2007-04-10 KR KR1020087028465A patent/KR101061328B1/ko not_active IP Right Cessation
- 2007-04-10 EA EA200801998A patent/EA014919B1/ru not_active IP Right Cessation
- 2007-04-10 AP AP2008004640A patent/AP2408A/xx active
- 2007-04-10 MX MX2008012456A patent/MX2008012456A/es active IP Right Grant
- 2007-04-10 AT AT07734320T patent/ATE513831T1/de active
- 2007-04-10 PL PL07734320T patent/PL2013208T3/pl unknown
- 2007-04-10 JP JP2009505983A patent/JP4436892B2/ja not_active Expired - Fee Related
- 2007-04-10 AU AU2007242555A patent/AU2007242555B2/en not_active Ceased
- 2007-04-10 RS RSP-2008/0484A patent/RS20080484A/sr unknown
- 2007-04-10 WO PCT/IB2007/001001 patent/WO2007122466A1/en active Application Filing
- 2007-04-10 ES ES07734320T patent/ES2366239T3/es active Active
- 2007-04-10 CA CA2649775A patent/CA2649775C/en not_active Expired - Fee Related
- 2007-04-10 CN CN2007800198932A patent/CN101454320B/zh not_active Expired - Fee Related
- 2007-04-10 ME MEP-238/08A patent/MEP23808A/xx unknown
- 2007-04-10 RS RS20110363A patent/RS51885B/en unknown
- 2007-04-10 DK DK07734320.0T patent/DK2013208T3/da active
- 2007-04-10 SI SI200730675T patent/SI2013208T1/sl unknown
- 2007-04-10 MY MYPI20084131A patent/MY148583A/en unknown
- 2007-04-10 NZ NZ571540A patent/NZ571540A/en not_active IP Right Cessation
- 2007-04-11 NL NL2000583A patent/NL2000583C2/nl not_active IP Right Cessation
- 2007-04-18 UY UY30291A patent/UY30291A1/es not_active Application Discontinuation
- 2007-04-18 AR ARP070101657A patent/AR060525A1/es not_active Application Discontinuation
- 2007-04-19 PE PE2007000483A patent/PE20080192A1/es not_active Application Discontinuation
- 2007-04-19 GT GT200700035A patent/GT200700035A/es unknown
- 2007-04-20 TW TW096114037A patent/TWI337609B/zh not_active IP Right Cessation
- 2007-04-20 DO DO2007000080A patent/DOP2007000080A/es unknown
- 2007-04-20 US US11/737,966 patent/US7902195B2/en not_active Expired - Fee Related
- 2007-04-20 PA PA20078724201A patent/PA8724201A1/es unknown
- 2007-10-04 UA UAA200812397A patent/UA92637C2/ru unknown
-
2008
- 2008-09-29 NO NO20084129A patent/NO20084129L/no not_active Application Discontinuation
- 2008-09-29 ZA ZA200808283A patent/ZA200808283B/xx unknown
- 2008-09-30 CR CR10327A patent/CR10327A/es unknown
- 2008-10-07 IL IL194591A patent/IL194591A/en not_active IP Right Cessation
- 2008-10-08 EC EC2008008803A patent/ECSP088803A/es unknown
- 2008-10-17 CU CU20080194A patent/CU23777B7/es active IP Right Grant
- 2008-10-17 TN TNP2008000408A patent/TNSN08408A1/fr unknown
- 2008-10-21 SV SV2008003074A patent/SV2008003074A/es unknown
- 2008-10-21 MA MA31321A patent/MA30352B1/fr unknown
-
2009
- 2009-11-10 HK HK09110478.1A patent/HK1133875A1/xx not_active IP Right Cessation
-
2011
- 2011-07-20 HR HR20110539T patent/HRP20110539T1/hr unknown
- 2011-07-25 CY CY20111100731T patent/CY1111739T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR060525A1 (es) | Piridin [3,4-b] pirazinonas. composiciones farmaceuticas | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR058124A1 (es) | Derivados de ftalazinona como inhibidores de parp-1 | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
| AR073396A1 (es) | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| AR048669A1 (es) | Derivados biciclicos de bisamida | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos | |
| AR075510A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| UA117800C2 (uk) | Похідні урацилу або тиміну для лікування гепатиту с | |
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| UY31014A1 (es) | Derivados de ftalazinona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |